Skip to main content
OpenTrials

Clinical trial condition

Neisseriaceae Infections

Explore clinical trials studying Neisseriaceae Infections. Study availability and eligibility vary by location and protocol.

400 public trials 21 recruiting studies
Refine in advanced search Browse all conditions

Neisseriaceae Infections trial results

Completed

Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines

NCT00463437

Conditions
Acellular Pertussis, Actinomycetales Infections, Bacterial Infections, +38 more
Locations
  • GSK Investigational Site Bad Saulgau, Baden-Wurttemberg, Germany
  • GSK Investigational Site Bönnigheim, Baden-Wurttemberg, Germany
  • GSK Investigational Site Bretten, Baden-Wurttemberg, Germany
  • GSK Investigational Site Ettenheim, Baden-Wurttemberg, Germany
View all 63 locations
View Trial Details
Completed

Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination

NCT02986854

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +7 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Huntsville, Alabama, United States
  • GSK Investigational Site Chandler, Arizona, United States
  • GSK Investigational Site Anaheim, California, United States
View all 37 locations
View Trial Details
Completed

Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children

NCT00474266

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Espoo, Finland
  • GSK Investigational Site Helsinki, Finland
  • GSK Investigational Site Helsinki, Finland
  • GSK Investigational Site Jarvenpaa, Finland
View all 14 locations
View Trial Details
Completed

Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children

NCT00674583

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Draguignan, France
  • GSK Investigational Site Laon, France
  • GSK Investigational Site Le Havre, France
  • GSK Investigational Site Lingolsheim, France
View all 31 locations
View Trial Details
Completed

Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination

NCT01934140

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • Research Institute for Tropical Medicine Muntinlupa City, National Capital Region, Philippines
  • Philippine General Hospital Manila, Philippines
View Trial Details
Completed

Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents

NCT02946385

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +7 more
Locations
  • GSK Investigational Site Espoo, Finland
  • GSK Investigational Site Helsinki, Finland
  • GSK Investigational Site Helsinki, Finland
  • GSK Investigational Site Jarvenpaa, Finland
View all 17 locations
View Trial Details

Related conditions